lapatinib has been researched along with Neoplasms in 123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (29.27) | 29.6817 |
| 2010's | 66 (53.66) | 24.3611 |
| 2020's | 21 (17.07) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, R; Cai, X; Forrester, J; Lai, CJ; Qian, C; Qu, H; Wang, J; Yin, L; Zhai, HX | 1 |
| Bell, RL; Bouska, J; Davidsen, SK; Hu, X; Hubbard, RD; Johnson, EF; Kovar, P; Mantei, RA; Osterling, DJ; Sheppard, GS; Tucker, L; Wang, GT; Wang, J; Wilsbacher, JL; Zhang, Q | 1 |
| Aertgeerts, K; Habuka, N; Hirokawa, A; Ishikawa, T; Iwamoto, K; Jennings, A; Miki, H; Ohta, Y; Sang, BC; Skene, R; Snell, G; Sogabe, S; Tanaka, T; Yano, J; Zou, H | 1 |
| Debnath, B; Ding, J; Kazemi, R; Long, YQ; Neamati, N; Odde, S; Sanchez, TW; Wang, Y; Xie, H; Xu, S; Xu, ZL; Yang, LM; Zeng, LF; Zheng, YT | 1 |
| Chen, LW; Duan, YT; Tang, DJ; Tao, XX; Wang, PF; Xu, C; Yang, MR; Zhu, HL | 1 |
| Abouzid, KAM; Lasheen, DS; Milik, SN; Serya, RAT | 1 |
| Abbas, SY; Ammar, YA; Belal, A; Mehany, ABM; Mohamed, YA; Ragab, A; Sh El-Sharief, AM | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Bansal, R; Malhotra, A | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
| Chandrasekar, MJN; Nagarjuna, P; Patnaik, SK; Ramamurthi, D; Swaroop, AK | 1 |
| Ai, L; He, Q; Jiang, L; Luo, P; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y | 1 |
| Werfel, TA | 1 |
| Harada, Y; Ikeda, S; Kai, K; Kimura, S; Kitamura, S; Kurihara, Y; Nakamura, H; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N | 1 |
| Jo, W; Kim, CS; Kim, M; Kim, S; Lee, C; Lee, KH; Oh, J; Park, C; Park, J; Ryu, HS; Seo, JK | 1 |
| Hao, SJ; Wu, FG; Zhu, YX | 1 |
| Shridhar Wakte, P; Sopanrao Wakure, B; Tanaji Mane, P | 1 |
| Deeken, J; He, AR; Hwang, J; Lynce, F; Marshall, J; Petricoin, EF; Pishvaian, MJ; Pohlmann, PR; Smaglo, B; Subramaniam, DS; Wang, H | 1 |
| Li, H; Sui, S; Wang, L; Xu, S; Zhang, L; Zhang, X; Zheng, X | 1 |
| Chevrier, R; Chollet, P; Devaud, H; Dubray-Longeras, P; Durando, X; Kwiatkowski, F; Mouret-Reynier, MA; Poirier, C; Thivat, E; Vacher, L; van Praagh-Doreau, I | 1 |
| Bello, M; Guadarrama-García, C; Rodriguez-Fonseca, RA | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
| Chang, WT; Feng, YH; Lee, K; Liu, PY; Wu, SN | 1 |
| Adjibade, P; Gauthier, WN; Khandjian, EW; Ledoux, N; Mazroui, R; Nkurunziza, M; Simoneau, B | 1 |
| Cai, N; Cheng, K; Liang, H; Wen, J; Xiong, Y; Zhang, W; Zhang, Y; Zhu, J | 1 |
| Collins, DM; Conlon, NT; Crown, J; Diala, I; Eli, LD; Kooijman, JJ; Lalani, AS; Mulder, WR; van Gerwen, SJC; Zaman, GJR | 1 |
| Zhan, CG; Zheng, F; Zhou, S | 1 |
| Banerji, D; Majumder, A; Moasser, MM; Olshen, A; Sandhu, M; Steri, V | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Chacko, AR; Hilkens, J; Piyush, T; Rhodes, JM; Sindrewicz, P; Yu, LG | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Arya, N; Beelen, AP; Coker, SA; Dees, EC; Gainer, SD; Koch, KM; Lewis, LD; Reddy, NJ | 1 |
| Bello, M; Correa-Basurto, J; García, B; Saldaña-Rivero, L; Sánchez-Espinosa, VA | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Aster, JC; Brown, M; Jiang, P; Johnson, C; Lee, W; Li, X; Liu, JS; Liu, XS | 1 |
| Bittner, ML; Chao, S; Datta, A; Hua, J; Katiyar, A; Lopes, R; Mohanty, A | 1 |
| Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW | 1 |
| Huang, MQ; Kocan, GP; Li, F; Pai, S | 1 |
| Coker, SA; Hurwitz, HI; Jordaan, P; Lewis, LD; Sharma, S; Wang, D; Zarate, JP | 1 |
| Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
| Albanell, J; Dalmases, A; Rojo, F; Rovira, A | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Christensen, SD; Chung, V; Gadgeel, SM; Hoering, A; Kingsbury, L; Kurzrock, R; Lew, DL; LoRusso, P; Smith, DC; Synold, TW | 1 |
| Fan, C; Guo, Z; Li, Y; Lin, D; Yang, S; Yang, Y; Zhang, L; Zhao, S; Zhu, J | 1 |
| Li, J; LoRusso, P; Wiegand, R; Wu, J | 1 |
| Arya, N; Botbyl, J; Cartee, L; Chu, QS; Devriese, LA; Koch, KM; Ma, WW; Matthys, GM; Mergui-Roelvink, M; Orford, KW; Robidoux, A; Schellens, JH; Stephenson, JJ | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 1 |
| Baselga, J; Chandarlapaty, S; de Stanchina, E; Huang, X; Jiang, X; Liu, N; Monian, P; Qin, AC; Rodrik-Outmezguine, V; Rosen, N; Schneider, C; Toy, W; Will, M; Yao, Z | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Nolting, M; Schneider-Merck, T; Trepel, M | 1 |
| Baumann, C; Gusenbauer, S; Kéri, G; Őrfi, L; Pénzes, K; Szabadkai, I; Torka, R; Ullrich, A | 1 |
| Moasser, MM | 1 |
| Abdel-Rahman, O; Fouad, M | 2 |
| Chen, YF; Fu, LW; Hu, YP; Huang, ZC; Ma, SL; Wang, F; Wang, XK | 1 |
| Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Nishio, K; Sakai, K; Togashi, Y | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ | 1 |
| Akgullu, C; Aksun, S; Bilgen, M; Boyacioglu, M; Demirci, B; Eryilmaz, U; Ilgenli, TF; Yalinkilinc, HS | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E | 1 |
| Arya, N; Burris, HA; Fleming, RA; Gadgeel, S; Jones, SF; Koch, KM; Loftiss, J; LoRusso, PM; Pandite, L; Weber, BL | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Goodin, S; Medina, PJ | 1 |
| Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Chen, G; Liu, BR; Xie, L | 1 |
| Beelen, AP; Cohen, RB; Koch, KM; Lewis, LD; Lewis, NL; Mackay, K; Reddy, NJ; Stead, A; Whitehead, B | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Obajimi, O | 1 |
| Tannock, IF | 1 |
| Chen, LM; Chien, AJ; Dubey, S; Fong, L; Huang, Y; Hylton, NM; Illi, JA; Jahan, TM; Kashani-Sabet, M; Ko, AH; Koch, KM; Korn, WM; Moasser, MM; Rosenberg, JE; Ryan, CJ; Small, EJ; Yeh, BM | 1 |
| Arya, N; Burris, HA; Fleming, RA; Jones, SF; Koch, KM; Pandite, L; Smith, DA; Spector, N; Taylor, CW; Versola, MJ; Wilding, G | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| Schneider-Merck, T; Trepel, M | 1 |
| Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Anderson, T; Fleming, M; Galsky, MD; Mahoney, JM; Midwinter, D; Nagarwala, Y; Neubauer, M; Vocila, L; Von Hoff, DD; Zaks, TZ | 1 |
| Clay, TM; Devi, G; Hartman, ZC; Hobeika, A; Lyerly, HK; Morse, MA; Osada, T | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H | 1 |
| Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Fowler, MB; Telli, ML; Witteles, RM | 1 |
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
| Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A | 1 |
| Arkhipov, A; Dror, RO; Eastwood, MP; Jumper, J; Kim, ET; Kuriyan, J; Shan, Y; Shaw, DE; Zhang, X | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
| Gustafson, DL; Hudachek, SF | 1 |
| Alligood, KJ; Keith, BR; Liu, LH; Ma, H; Mullin, RJ; Owens, G; Rusnak, DW; Spector, NL; Xia, W | 1 |
| Bacus, S; Blackwell, KL; Bremer, TM; Burris, H; Dees, EC; Dowlati, A; Ellis, MJ; Harris, J; Hurwitz, H; Koch, KM; Liu, L; Man, AK; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A; Xia, W | 1 |
| Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A | 1 |
| Rabindran, SK | 1 |
| Waltz, E | 1 |
| Dolder, CR; Nelson, MH | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Lackey, KE | 1 |
| Johnston, SR; Leary, A | 1 |
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Boyle, SN; Koleske, AJ | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Lewis, LD | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Giordano, S; Petrelli, A | 1 |
| Kopper, L | 1 |
| Cheng, J; Gilmer, T; Greshock, J; Lee, K; Martin, AM; Rusnak, D; Weber, BL; Wooster, R; Zaks, T | 1 |
37 review(s) available for lapatinib and Neoplasms
| Article | Year |
|---|---|
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Models, Molecular; Neoplasms; Point Mutation; Protein Domains; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Topics: Antibodies, Monoclonal; ErbB Receptors; Humans; Lapatinib; Ligands; Neoplasms; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2022 |
The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.
Topics: Acetaminophen; Antineoplastic Agents; Antioxidants; Apoptosis; Artemisinins; Auranofin; Cell Death; Cisplatin; Epigenesis, Genetic; Fatty Acids; Ferroptosis; Haloperidol; Humans; Indoles; Iron; Lapatinib; Mevalonic Acid; NADP; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxygen; Quinolines; Reactive Oxygen Species; Sorafenib; Spiro Compounds; Sulfasalazine; Trigonella | 2020 |
Clinical data mining reveals analgesic effects of lapatinib in cancer patients.
Topics: Analgesics; Anti-Inflammatory Agents; Data Mining; Drug Repositioning; Humans; Inflammation; Lapatinib; Neoplasms; Prostaglandin-E Synthases | 2021 |
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Signal Transduction; Translational Research, Biomedical; Trastuzumab | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatigue; Humans; Lapatinib; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Lapatinib; Neoplasms; Pruritus; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
[PI3K and mTOR pathway and molecular targeted agents].
Topics: Animals; Antibodies, Monoclonal, Humanized; Class I Phosphatidylinositol 3-Kinases; Drug Discovery; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
[Stem cell-targeted therapy--a new strategy for cancer treatment].
Topics: Adenosine; Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Differentiation; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Humans; Lapatinib; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidinones; Quinazolines; Signal Transduction; Triazines; Wnt Proteins | 2008 |
Lapatinib as a chemotherapeutic drug.
Topics: Clinical Trials as Topic; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left | 2011 |
Antitumor activity of HER-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2005 |
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PubMed; Quinazolines | 2006 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Topics: Animals; Drug Design; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Structure; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2006 |
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Dissecting kinase signaling pathways.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Food effects on oral agents.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Food-Drug Interactions; Humans; Lapatinib; Neoplasms; Quinazolines | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Lapatinib: a sword with two edges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
22 trial(s) available for lapatinib and Neoplasms
| Article | Year |
|---|---|
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, ErbB-2 | 2019 |
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Everolimus; Female; Humans; Incidence; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; United States; Young Adult | 2013 |
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Dietary Fats; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2014 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Effects of food on the relative bioavailability of lapatinib in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Solubility | 2009 |
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Injections, Intravenous; Lapatinib; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2009 |
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome; United States | 2012 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Cell Survival; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2005 |
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome | 2005 |
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lapatinib; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Quinazolines | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
64 other study(ies) available for lapatinib and Neoplasms
| Article | Year |
|---|---|
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Enzyme Inhibitors; ErbB Receptors; Female; HeLa Cells; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Mice; Mice, Inbred C57BL; Neoplasms; Rats; Receptor, ErbB-2; Receptor, IGF Type 1; Structure-Activity Relationship | 2010 |
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Topics: Allosteric Regulation; Antineoplastic Agents; Crystallography, X-Ray; Drug Design; Enzyme Activation; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship | 2011 |
Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties.
Topics: Antineoplastic Agents; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Integration | 2012 |
Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Nitroimidazoles; Protein Kinase Inhibitors; Pyrazoles; Receptor, ErbB-2 | 2016 |
Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Isatin; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors | 2018 |
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |
Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; HMGB1 Protein; Humans; Lapatinib; Mice; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2022 |
Assessment of the Immune Response to Tumor Cell Apoptosis and Efferocytosis.
Topics: Animals; Apoptosis; Lapatinib; Macrophages; Mice; Necrosis; Neoplasms; Phagocytosis; Tumor Microenvironment | 2022 |
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Mutation; Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab | 2023 |
Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia.
Topics: Animals; Cell Line, Tumor; Epigenesis, Genetic; Hyperglycemia; Lapatinib; Mice; Neoplasms; Neuregulin-1 | 2023 |
Membrane fusion-mediated delivery of small-molecule HER2 tyrosine kinase inhibitor for effective tumor chemosensitization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lapatinib; Liposomes; Membrane Fusion; Neoplasms; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Enhancement in the therapeutic potential of lapatinib ditosylate against breast cancer by the use of β-cyclodextrin based ternary nanosponge system.
Topics: Animals; beta-Cyclodextrins; Calorimetry, Differential Scanning; Female; Lapatinib; Neoplasms; Rats; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2023 |
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin.
Topics: A549 Cells; Animals; Carbamates; Cell Movement; Cisplatin; Dipeptides; DNA Methylation; Epigenesis, Genetic; Ferroptosis; Heterografts; Histones; Humans; Lapatinib; Mice; Neoplasm Invasiveness; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Pyridines; Topotecan | 2020 |
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Lapatinib; Male; Medication Adherence; Middle Aged; Neoplasms; Prospective Studies | 2020 |
Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Computational Biology; ErbB Receptors; Humans; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2020 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in Cardiomyocytes.
Topics: Action Potentials; Animals; Humans; Ion Channels; Ion Transport; Isoproterenol; Lapatinib; Mice; Myocytes, Cardiac; Neoplasms; Potassium; Potassium Channels; Protein Kinase Inhibitors; Rats; Sodium; Sorafenib | 2020 |
Treatment of cancer cells with Lapatinib negatively regulates general translation and induces stress granules formation.
Topics: Cell Line, Tumor; Cytoplasmic Granules; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Humans; Lapatinib; MCF-7 Cells; Neoplasms; Phosphorylation; Protein Biosynthesis; Up-Regulation | 2020 |
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2021 |
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice, Inbred NOD; Neoplasms; Phosphorylation; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2021 |
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
Topics: Blood Proteins; Cell Line, Tumor; Cell Membrane; Endocytosis; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Galectin 3; Galectins; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-1; Mutation; Neoplasms; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Lapatinib; Male; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2017 |
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Dimerization; ErbB Receptors; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Profiling; Genomics; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; RNA, Small Interfering; Software; Transcriptome; Treatment Outcome | 2018 |
A Bayesian approach to determine the composition of heterogeneous cancer tissue.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Cell Count; Cell Line, Tumor; Computer Simulation; Humans; Lapatinib; Neoplasms; Probability; Sirolimus | 2018 |
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2018 |
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis.
Topics: Chromatography, Liquid; Drug Stability; Humans; Kidney Failure, Chronic; Lapatinib; Linear Models; Neoplasms; Quinazolines; Renal Dialysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Young Adult | 2019 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Neoplasms, Experimental; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Solubility; Structure-Activity Relationship | 2013 |
A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.
Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Lapatinib; Limit of Detection; Neoplasms; Quinazolines; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet | 2014 |
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Topics: Apoptosis; Cell Line, Tumor; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Signaling System; MCF-7 Cells; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2014 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Lapatinib; Ligands; Mice; Myelin Proteins; Neoplasms; Nogo Receptor 1; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Cell Surface; Transcription, Genetic; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Two dimensions in targeting HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2014 |
Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Burden; Vincristine | 2014 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles | 2015 |
S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Catalase; Glutathione; Heart Failure; Lapatinib; Male; Malondialdehyde; Myocardium; Neoplasms; Oxidative Stress; Quinazolines; Rats, Wistar; S100 Proteins; Superoxide Dismutase; Trastuzumab | 2015 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left | 2008 |
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Quinazolines; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Effects of food on bioavailability of lapatinib: useful data, wrong conclusion.
Topics: Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Neoplasms; Quinazolines; Reference Values; Risk Assessment | 2009 |
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lapatinib; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cancer Vaccines; Clinical Trials as Topic; Humans; Immunotherapy; Lapatinib; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; T-Lymphocytes; Trastuzumab | 2011 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Topics: Amino Acid Sequence; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplasms; Point Mutation; Protein Folding; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Sequence Alignment; Signal Transduction | 2012 |
Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Liver; Mice; Models, Biological; Neoplasms; Quinazolines; Tissue Distribution | 2013 |
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2002 |
GlaxoSmithKline cancer drug threatens Herceptin market.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Lapatinib; Marketing; Neoplasms; Quinazolines; Trastuzumab; United States | 2005 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Gene Dosage; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Lapatinib; Models, Molecular; Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; ROC Curve; Tumor Cells, Cultured | 2008 |